Moss, 11 February 2026

Gentian Diagnostics ASA announces an update on the development of its NT proBNP
assay. Recent investigations have confirmed that the current assay version does
not demonstrate sufficiently robust performance in the lower concentration
ranges, particularly around clinically important cut off levels.

Based on these findings, Gentian has identified several measures that may
enhance assay performance